Promise and Implementation of Proteomic Prostate Cancer Biomarkers
Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers al...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-08-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2075-4418/8/3/57 |
| _version_ | 1798040177108582400 |
|---|---|
| author | Agnieszka Latosinska Maria Frantzi Axel S. Merseburger Harald Mischak |
| author_facet | Agnieszka Latosinska Maria Frantzi Axel S. Merseburger Harald Mischak |
| author_sort | Agnieszka Latosinska |
| collection | DOAJ |
| description | Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers alone and or in combination with clinical and pathological risk calculators are expected to improve on decreasing the unnecessary biopsies, stratify low risk patients, and predict response to treatment. To this end, significant efforts have been undertaken to identify novel biomarkers that can accurately discriminate between indolent and aggressive cancer forms and indicate those men at high risk for developing prostate cancer that require immediate treatment. In the era of “big data” and “personalized medicine” proteomics-based biomarkers hold great promise to provide clinically applicable tools, as proteins regulate all biological functions, and integrate genomic information with the environmental impact. In this review article, we aim to provide a critical assessment of the current proteomics-based biomarkers for prostate cancer and their actual clinical applicability. For that purpose, a systematic review of the literature published within the last 10 years was performed using the Web of Science Database. We specifically discuss the potential and prospects of use for diagnostic, prognostic and predictive proteomics-based biomarkers, including both body fluid- and tissue-based markers. |
| first_indexed | 2024-04-11T22:03:52Z |
| format | Article |
| id | doaj.art-27d7e632ea1a4ee7a3862682c7273426 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-04-11T22:03:52Z |
| publishDate | 2018-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-27d7e632ea1a4ee7a3862682c72734262022-12-22T04:00:48ZengMDPI AGDiagnostics2075-44182018-08-01835710.3390/diagnostics8030057diagnostics8030057Promise and Implementation of Proteomic Prostate Cancer BiomarkersAgnieszka Latosinska0Maria Frantzi1Axel S. Merseburger2Harald Mischak3Mosaiques Diagnostics GmbH, 30659 Hannover, GermanyMosaiques Diagnostics GmbH, 30659 Hannover, GermanyDepartment of Urology, University Clinic of Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, GermanyMosaiques Diagnostics GmbH, 30659 Hannover, GermanyProstate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers alone and or in combination with clinical and pathological risk calculators are expected to improve on decreasing the unnecessary biopsies, stratify low risk patients, and predict response to treatment. To this end, significant efforts have been undertaken to identify novel biomarkers that can accurately discriminate between indolent and aggressive cancer forms and indicate those men at high risk for developing prostate cancer that require immediate treatment. In the era of “big data” and “personalized medicine” proteomics-based biomarkers hold great promise to provide clinically applicable tools, as proteins regulate all biological functions, and integrate genomic information with the environmental impact. In this review article, we aim to provide a critical assessment of the current proteomics-based biomarkers for prostate cancer and their actual clinical applicability. For that purpose, a systematic review of the literature published within the last 10 years was performed using the Web of Science Database. We specifically discuss the potential and prospects of use for diagnostic, prognostic and predictive proteomics-based biomarkers, including both body fluid- and tissue-based markers.http://www.mdpi.com/2075-4418/8/3/57active surveillancebiomarkersdiagnosisProstate Cancerproteomics |
| spellingShingle | Agnieszka Latosinska Maria Frantzi Axel S. Merseburger Harald Mischak Promise and Implementation of Proteomic Prostate Cancer Biomarkers Diagnostics active surveillance biomarkers diagnosis Prostate Cancer proteomics |
| title | Promise and Implementation of Proteomic Prostate Cancer Biomarkers |
| title_full | Promise and Implementation of Proteomic Prostate Cancer Biomarkers |
| title_fullStr | Promise and Implementation of Proteomic Prostate Cancer Biomarkers |
| title_full_unstemmed | Promise and Implementation of Proteomic Prostate Cancer Biomarkers |
| title_short | Promise and Implementation of Proteomic Prostate Cancer Biomarkers |
| title_sort | promise and implementation of proteomic prostate cancer biomarkers |
| topic | active surveillance biomarkers diagnosis Prostate Cancer proteomics |
| url | http://www.mdpi.com/2075-4418/8/3/57 |
| work_keys_str_mv | AT agnieszkalatosinska promiseandimplementationofproteomicprostatecancerbiomarkers AT mariafrantzi promiseandimplementationofproteomicprostatecancerbiomarkers AT axelsmerseburger promiseandimplementationofproteomicprostatecancerbiomarkers AT haraldmischak promiseandimplementationofproteomicprostatecancerbiomarkers |